ABBV

Healthcare / Pharmaceuticals / Drug Manufacturers - General
AbbVie discovers, develops, manufactures, and sells branded pharmaceutical products globally, generating recurring revenue from patent-protected drugs and therapies across immunology, oncology, virology, and specialty care.
Recommended: koller_dcf
$212.32
Current market price
Source: FMP +EDGAR

Market implications

What the market is baking into $212.32. Does not change with your assumptions.

Implied terminal growth (cv_g)
4.63%
solved so market model = $212.32 with the analyst inputs below
WACC (CAPM)
5.22%
β: 0.30 · Rf: 4.0% · ERP: 5.5%
Ke: 5.68% · Kd(AT): 2.69%
E/V: 84.6% · D/V: 15.4%
CV ROIC (from historical)
12.08%
CV NOPLAT = $10,427M
Tax rate / Op cash / Shares
Forecast tax: 35.8%
Op cash %: 3.0%
Shares: 1,780M
5-year consensus forecast
YearRevenue ($M)EBITDA ($M)
2025 60,965 20,866
2026 67,284 23,029
2027 72,634 24,860
2028 77,836 26,641
2029 81,973 28,057
Validation: set your view's WACC = 5.22%, cv_g = 4.63%, tax = 35.8%. Your model should produce exactly $212.32.

Your view

Yellow cells are editable.

Your model output

Model share price: $63.80
vs market: -70.0%
Enterprise value: $181,492M
Operating value: $199,474M
Continuing value: $137,300M
Debt: $67,864M
Excess cash: $3,865M
Residuals: B/S 0.0M · TFI 0.0M · TII 0.0M · CFI 0.0M

Forecast ratios (yellow cells)

Held constant across forecast years (H–M). Defaults are the most recent historical ratio. Override to express a different view (margin compression, working-capital efficiency, etc.).

Income statement

D&A % of revenue 14.89%
Non-op losses % of rev 0.00%

Working capital

AR % of revenue 19.38%
Unbilled rev % of rev 0.00%
Inventory % of rev 7.42%
Other CA % of rev 8.75%
AP % of rev 8.75%
Other ST liab % of rev 47.95%

Long-term assets & liab

LT investments % of rev 0.50%
Net fixed assets % of rev 7.84%
Other LT assets % of rev 17.51%
Other LT liab % of rev 56.78%

Consensus forecast (your editable copy)

Defaults are FMP analyst consensus. Edit any cell; Recalculate uses these values.

YearRevenue ($M)EBITDA ($M) EBITDA marginYoY rev growth
2025 34.2% —
2026 34.2% +10.4%
2027 34.2% +8.0%
2028 34.2% +7.2%
2029 34.2% +5.3%
CV NOPLAT: $18,743M · CV ROIC: 21.71%

Sensitivity: model price by WACC × cv_g

5×5 grid centered on your assumptions. Green cells > market, red < market. Computes 25 model runs (~10s).

Click “Run sensitivity” above.

Monte Carlo simulation

Sample WACC, cv_g, revenue multiplier, and EBITDA margin shift; see distribution of fair value.

Distribution widths (σ):
Each sample: draws values from normal distributions centered on your current assumptions, runs the full DCF, records the model price. 100 samples ≈ 60s.

Configure σ above and click “Run Monte Carlo”.

Peers (LLM-proposed comparables)

3–5 publicly-traded comps with rationale + suggested multiples. ~$0.002/call, cached 30d.

▸ expand

Red flags (accounting / governance / operational / liquidity)

Severity-tiered concerns with explicit evidence. ~$0.004/call, cached 30d.

▸ expand

Recent news (web search)

Material items from the last 60 days with source links. ~$0.02–0.05/call, cached 6h.

▸ expand

Snapshots

No saved snapshots yet.